Afya (AFYA) Q4 2023: B2B Digital Revenue Jumps 64%, Fueling Margin Expansion Narrative
B2B digital contracts surged 64% in 2023, underpinning Afya’s multi-segment margin expansion plans for 2024. Management’s guidance signals confidence in operational leverage and digital monetization, with all three business lines expected to outpace sector growth. Investors should track digital and continuing education momentum as Afya leans into high-visibility, recurring revenue streams and disciplined capital allocation.
Summary
- B2B Digital Acceleration: New pharma contracts and recurring product launches are driving outsized digital revenue growth.
- Margin Expansion Across Segments: Operational leverage and full integration of recent acquisitions support EBITDA improvement in 2024.
- Guidance Confidence: Management signals high predictability, prioritizing organic growth and operational discipline over deal-driven expansion.
Business Overview
Afya is a leading Brazilian medical education and digital health platform, generating revenue through three primary segments: undergraduate medical education, continued education, and digital health services. Its core business is the operation of medical schools and related programs, complemented by digital solutions for physicians and B2B pharma partnerships. Recurring tuition, digital subscriptions, and B2B contracts form the backbone of Afya’s predictable, cash-generative model.
Performance Analysis
Afya delivered broad-based growth in Q4 and full-year 2023, with notable strength in digital and continued education segments. Adjusted net revenue rose sharply, primarily on higher medical school tuition, successful integration of recent campus acquisitions, and robust expansion in digital services. Operating leverage was evident as both adjusted EBITDA and net income improved, though the margin saw a modest dip due to mix shift and early-stage campus ramp-up costs.
Digital health services and continued education outpaced the core undergraduate segment in growth rate, reflecting Afya’s push into scalable, asset-light revenue streams. Digital B2B revenues grew 64% organically, fueled by pharma marketing campaigns and the launch of recurring analytics products. Continued education also saw double-digit expansion, supported by new campus openings and strong intake in specialization programs.
- Digital Monetization Leverage: B2B and B2P digital revenues are scaling faster than legacy tuition, enhancing margin potential.
- Acquisition Synergy Realization: Rapid integration of recent campus buys contributed to seat growth and operational efficiency.
- Cash Flow Strength: Operating cash conversion remained best-in-class, supporting buybacks and debt reduction without growth trade-offs.
Afya’s business model showed resilience and high predictability, with all segments contributing to growth and cash generation. The company enters 2024 with a clean balance sheet, disciplined capital allocation, and a visible path to margin expansion.
Executive Commentary
"Our digital health services revenue marked another great result with a 21% increase compared to 2022, pure organically, reaching a net revenue of R$229 million. This outcome underscores the vast opportunity in digital services, driven by the ramp-up in B2B engagements, securing new contracts with pharmaceutical industry companies, and the continuous expansion in B2B contracts."
Virgílio Vigibon, CEO
"We saw during 2023 the increases in terms of contracts within the pharmaceutical industry come from products that we call campaign products. These kind of products drive our growth during 2023 and for the next year, for 2024. On top of that, we launched at the end of 2023 some recurring products to the pharmaceutical companies as well. We are excited for the perspective of these offers for the pharmaceutical companies and I think we have this additional growth in 2024 with this new product that we launched that we call RRX Insights."
Luiz André Blanco, CFO
Strategic Positioning
1. Digital Health Scale and B2B Monetization
Afya’s digital health segment, which includes physician-facing apps and pharma B2B contracts, is now a key driver of both growth and margin expansion. Active B2B partnerships with major pharmaceutical companies have shifted from one-off campaigns to recurring product offerings, such as RRX Insights, unlocking higher-value, repeatable revenue streams. The digital segment’s rapid growth, particularly in B2B, positions Afya to capitalize on the digitalization of healthcare marketing and analytics in Brazil.
2. Operational Leverage in Continued Education
Continued education, which includes post-graduate and specialization programs for physicians, delivered over 35% revenue growth and saw student numbers rise by more than 60%. New campus launches and higher student fill rates are driving operational leverage, with management projecting further margin gains in 2024 as these locations mature and scale.
3. Integration and Margin Expansion in Undergraduate Segment
Recent campus acquisitions, notably Unima and FCM Jaboatão, have been fully integrated, enabling Afya to realize cost synergies and curriculum standardization. 2024 will be the first full year with these campuses operating under Afya’s model, which is expected to drive margin expansion in the core medical education business as fixed costs are absorbed over a larger revenue base.
4. Capital Allocation Discipline and M&A Pipeline
Afya continues to prioritize capital discipline, favoring organic growth and accretive M&A with a focus on IRR (internal rate of return) over headline multiples. The company maintains an active but selective M&A pipeline, targeting institutions with high exposure to medical education and aiming for leverage-neutral, high-return transactions. Buybacks and debt reduction remain priorities, with free cash flow supporting both growth and shareholder returns.
5. ESG and Workforce Diversity Initiatives
Afya’s ESG (Environmental, Social, Governance) commitments are visible in renewable energy adoption, diversity targets, and community healthcare impact. 100% of educational operations are now powered by renewable energy, and the company is on track to reach 50% female leadership by 2030, reinforcing its long-term stakeholder value narrative.
Key Considerations
This quarter’s results highlight Afya’s evolution from a pure-play medical school operator to an integrated education and digital health ecosystem. The company’s ability to scale high-margin digital and continued education segments, while maintaining core undergraduate growth, is central to its investment case.
Key Considerations:
- Digital Revenue Mix Shift: Continued outperformance in B2B digital contracts could accelerate overall margin expansion and reduce cyclicality tied to student intake.
- Operational Leverage from Recent Acquisitions: Full-year integration of new campuses is expected to improve fixed cost absorption and profitability.
- Regulatory Supply Expansion: Potential authorization of up to 10,000 new medical seats in Brazil over the next six years could alter competitive dynamics, though Afya’s brand strength and scale should provide insulation.
- Selective M&A as Growth Lever: Management’s focus on IRR and disciplined multiples suggests future deals are likely to be strategically and financially accretive.
- Cash Flow and Capital Allocation: Strong operating cash conversion supports both reinvestment and shareholder returns, with no sign of capital strain from growth initiatives.
Risks
Regulatory uncertainty remains a key risk, with potential changes to seat allocation or injunction outcomes possibly impacting future growth rates or competitive intensity. Execution risk in scaling digital and continued education offerings, as well as integration of future acquisitions, could pressure margins if not managed tightly. Market dynamics, such as changes in physician demand or pharma marketing budgets, may affect digital segment momentum. Management’s guidance assumes continued strong demand and stable macro conditions, which should be monitored closely.
Forward Outlook
For Q1 2024, Afya guided to:
- Continued double-digit organic growth in all three segments: undergrad, continued education, and digital services
- Margin expansion across the business, supported by operational leverage and full-year integration of recent acquisitions
For full-year 2024, management raised guidance to:
- Net revenue of R$3.15–3.25 billion
- Adjusted EBITDA of R$1.3–1.4 billion
- CapEx of R$220–260 million, excluding earn-out payments
Management highlighted several factors that underpin this outlook:
- Strong student intake and seat occupancy, with no signs of demand softening
- Digital B2B pipeline and new product launches expected to drive further outperformance in digital segment
Takeaways
Afya’s Q4 print confirms its transition to a multi-engine growth story, with digital and continued education now driving incremental margin and cash flow. Operational discipline and capital allocation remain central, providing protection against sector volatility. Investors should monitor digital B2B execution and regulatory developments as key variables for 2024 and beyond.
- Digital and Continued Ed Outperformance: These segments are now material contributors, de-risking the legacy tuition model and setting up for further margin gains.
- Regulatory and Competitive Watch: Seat expansion and policy changes could alter the landscape, but Afya’s scale and brand provide relative resilience.
- Outlook Hinges on Digital Upside: Sustained B2B growth and successful recurring product adoption are the main levers for beating guidance and maintaining premium valuation.
Conclusion
Afya’s Q4 and 2023 results reinforce its status as a diversified, high-margin education and digital health platform. The company’s guidance and execution suggest continued outperformance, provided digital momentum and operational leverage are sustained.
Industry Read-Through
Afya’s rapid B2B digital revenue growth and margin expansion highlight a broader trend toward digitalization in healthcare education and pharma marketing. Competitors in medical education and digital health should note the importance of recurring B2B contracts and value-added analytics products. Regulatory seat expansion, if realized, could shift the Brazilian medical education landscape, favoring scaled players with integrated digital offerings. The sector’s evolution toward hybrid education and digital-enabled services will likely accelerate, with capital discipline and operational leverage emerging as key differentiators for long-term winners.